For research use only. Not for therapeutic Use.
Afatinib (Cat.No:I005096) is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) and HER2, used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. This small molecule inhibits downstream signaling in the EGFR pathway, blocking tumor cell proliferation and survival. By targeting both wild-type and mutant forms of EGFR, Afatinib offers an effective option for patients with advanced cancers resistant to other EGFR inhibitors. Ideal for clinical research and pharmaceutical development.
| Catalog Number | I005096 |
| CAS Number | 850140-72-6 |
| Molecular Formula | C24H25ClFN5O3 |
| Purity | ≥95% |
| Target | Protein Tyrosine Kinase/RTK |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 0.5 nM/0.4 nM/10 nM/14 nM (EGFR(wt)/EGFR(L858R)/EGFR(L858R/T790M) /HER2) |
| IUPAC Name | (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide |
| InChI | InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 |
| InChIKey | ULXXDDBFHOBEHA-CWDCEQMOSA-N |
| SMILES | CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4 |
